Bharat Parenterals Limited announces shareholder approval of two special resolutions
Bharat Parenterals Ltd · Pharmaceuticals & Biotechnology
What the filing says
- EGM held on October 23, 2026 approved issuance of equity shares of the Company on preferential basis by special resolution
- EGM approved making investments, giving loans, guarantees and providing security in excess of limits under Section 186(2) of the Companies Act, 2013
- Votes polled were 4879194 of 6891963 outstanding shares (70.7954%), with 4879194 in favour and 0 against on both resolutions
Why it's rated notable: Shareholders approved a preferential issue of equity shares at the EGM held October 23, 2026, but the filing states no issue size or amount, so the level stays at medium.
Figures checked against the filing by a second AI read, which corrected the first summary. About the business, not the share price.
Original filing
Announcement under Regulation 30 (LODR)-Preferential Issue
Read the filing on BSE (PDF) →Companies guiding to strong growth
Ranked by management's own guidance on revenue and margins — not by us.
Electrical Equipment
Sign up free to see all 6 →
See full rankingsRank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Other fundraise / allotment filings this fortnight
- Regency Fincorp reports Q2 & H1 FY27 results with AUM crossing ₹600 crore
- Raymond Realty Limited receives in-principle approval for preferential issue of shares
- OnEMI Technology Solutions allots 2,64,93,882 equity shares via preferential issue
- Natco Pharma allots 1,70,58,082 equity shares in Rights Issue at ₹750 each
- Capital Infra Trust submits post-Institutional Placement unit holding pattern
- Capital Infra Trust raises ₹1,115 crore via QIP for acquiring six HAM road assets
Summary written by Arthneeti from the company's filing with the stock exchange; check the original filing for full details. Arthneeti is a research and analytics platform, not a SEBI-registered investment adviser, and nothing here is a recommendation to buy or sell.